New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.43
1.09
+1.87%
Follow BMY
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $3.8B covered $1.3B of dividends and buybacks. Cash rose by $852.0M. What is a cash flow statement?
- Free cash flow
- $3.8B 91.8% of operating cash flow
- Returned to shareholders
- $1.3B 33.5% of free cash flow
- Debt, net
- −$1.0M repaid
- Change in cash
- +$852.0M over the period
| Operating cash flow | 4.2 |
|---|---|
| Capital expenditures | −0.3 |
| Free cash flow | 3.8 |
| Acquisitions, net | −1.1 |
| Into investments, net | −0.6 |
| Dividends | −1.3 |
| Shares issued, net | +0.1 |
| Change in cash | 0.9 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $2.0B | $1.1B | $3.4B | $4.2B |
| Capex | −$370M | −$347M | −$305M | −$344M |
| Free cash flow | $1.6B | $757M | $3.1B | $3.8B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+8 more quarters Free account |
1,085.00 | 2,678.00 | 3,316.00 | 2,162.00 |
Depreciation & Amortization |
977.00 | 594.00 | 594.00 | 626.00 | |
Non Cash Items (Other) |
1,566.00 | 645.00 | 128.00 | 1,200.00 | |
Accounts Receivable Change |
19.00 | 1,687.00 | (1,183.00) | (95.00) | |
Change in inventories |
71.00 | 14.00 | (36.00) | 133.00 | |
Change in payables and accrued liability |
(90.00) | 409.00 | (29.00) | 252.00 | |
Income tax paid |
(324.00) | 187.00 | (522.00) | 195.00 | |
Change in other assets and liabilities |
(1,330.00) | (5,131.00) | 1,146.00 | (292.00) | |
Other operating activities |
— | 21.00 | — | — | |
Operating Cash Flow |
1,974.00 | 1,104.00 | 3,393.00 | 4,181.00 | |
Capital expenditures |
(370.00) | (347.00) | (305.00) | (344.00) | |
Net Aquisitions |
(1,428.00) | 247.00 | 118.00 | (1,121.00) | |
Short Term Investments Change (Net) |
324.00 | (422.00) | (1,465.00) | (649.00) | |
Long-Term Investments Change (Net) |
16.00 | 391.00 | 38.00 | 10.00 | |
Investing cash flow |
(1,458.00) | (131.00) | (1,614.00) | (2,104.00) | |
Repayment/Issuance of Debt (Net) |
(4,734.00) | (179.00) | (1,350.00) | (1.00) | |
Equity Repurchase (Common, Net) |
— | (98.00) | 7.00 | 66.00 | |
Dividends Paid (Total) |
(1,262.00) | (1,283.00) | (1,287.00) | (1,287.00) | |
Other financial activities |
(128.00) | — | — | — | |
Financing cash flow |
(6,029.00) | (1,560.00) | (2,630.00) | (1,222.00) | |
Exchange Rate Adjustment |
5.00 | (48.00) | (10.00) | (3.00) | |
Change in Cash |
(5,508.00) | (635.00) | (861.00) | 852.00 | |
Beginning Cash |
0.00 | 10,218.00 | 0.00 | 0.00 | |
Ending Cash |
(5,508.00) | 9,583.00 | (861.00) | 852.00 | |
Stock Based Compensation |
133.00 | 146.00 | 135.00 | 138.00 | |
Dividends Paid (Common) |
(1,262.00) | (1,283.00) | (1,287.00) | (1,287.00) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
(1,654.00) | (2,834.00) | (624.00) | 193.00 | |
Investments Change (Net) |
340.00 | (31.00) | (1,427.00) | (639.00) | |
Issuance/Purchase of Shares |
— | (98.00) | 7.00 | 66.00 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026